INVEX THERAPEUTICS ORD
Invex Therapeutics receives tax rebate for neurological drug research
Clinical-stage biopharmaceutical company Invex Therapeutics (ASX: IXC) has announced it has received about £100,000 (A$186,000) in a research and development tax rebate from the UK government for the 2021 financial year. The rebate relates to research and development activities conducted by its subsidiary Invex UK, including research undertaken in the lead-up to a planned phase three […]
Invex Therapeutics opens first US clinical site for Presendin trials
Clinical-stage biopharmaceutical company Invex Therapeutics (ASX: IXC) has announced the opening of its first US-based clinical site at the Eye Wellness Centre in Texas. The centre is run by respected neuro-ophthalmologist Dr Rose Tang and will be integral to trials of the company’s lead candidate Presendin (sustained-release Exenatide) for neurological conditions relating to raised intracranial […]
Invex Therapeutics gets EU approval to develop Presendin for adolescents with idiopathic intracranial hypertension
A paediatric investigation plan (PIP) submitted by Invex Therapeutics (ASX: IXC) for the development of lead drug Presendin in the treatment of idiopathic intracranial hypertension (IIH) in adolescents has been accepted by the European Medicines Agency. The approval will allow Invex to develop Presendin for IIH patients who are under 18 years of age and […]
Invex Therapeutics to begin recruiting IIH patients in NZ for clinical trial following regulatory approvals
Invex Therapeutics (ASX: IXC) has secured approval to expand its Evolve phase III clinical trial into New Zealand, where it will evaluate its drug Presendin in patients with idiopathic intracranial hypertension (IIH). The New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) granted approval for the trial along with Invex getting the green light from […]
